Taken together, our data support a model in which EZH2 overexpression drives HB tumor progression through both canonical and noncanonical mechanisms, associated with dysregulated mitosis, altered PRC2 complex integrity, and potential epigenetic modulation of CDH1 signaling. The gene discussed is CDH1; the disease is hemoglobin measurement.